Global Myofascial Pain Syndrome (MPS) Treatment Market - Industry Trends and Forecast to 2028

Market Analysis and Insights : Global Myofascial Pain Syndrome (MPS) Treatment Market

Myofascial pain syndrome (MPS) treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 4.00% in the above-mentioned research forecast period. Rising geriatric population and increasing technological advancement for pain treatment will likely to drive the market growth.

Moreover, increasing focus of market players towards the development of non-opioid treatment options, rising level of muscle and other stress and increasing awareness for disease cause and its treatment options also boost up the market growth. Moreover, increasing research and development and rising healthcare expenditure act as opportunities for the market growth. But, sometimes adverse effect related to the drugs, strict regulatory framework and high cost of laser therapy among other may hamper the global myofascial pain syndrome (MPS) treatment market.

Myofascial pain syndrome (MPS) is a kind of musculoskeletal disorder that causes chronic pain in several body parts and sites.  The primary source of myofascial syndrome is myofascial trigger points and is responsible for production of localized or referred pain. Myofascial trigger points arises from the abnormal stress imposed on muscle fibres which can be the result of repetitive microtrauma or traumatic injury. Fibromyalgia and sleep problems are most common complications associated with myofascial pain syndrome. The most common symptoms associated with this disease involves deep, aching pain in muscle, a kind of tender knot in muscle, difficulty in sleeping among others. Myofascial pain syndrome can effectively be treated by the application of pain medications, relaxation techniques, physical therapy and trigger point injections among others.

As per the report published by WHO on November 2019, this has been suggested that musculoskeletal condition is one of the leading causes of disability worldwide which varies with age and diagnosis. It accounts for approximately 20% to 30% of overall worldwide population. The affected population is largely dependent upon the effective treatments and therapies hence expected to provide market with the lucrative growth. It is also estimated that myofascial pain syndrome (MPS) treatment market is growing with the CAGR of 4.00% in 2020.

Moreover market players are constantly engaged in development of effective therapies which is again boosting up the market growth.

For instance,

• In March 2019, Teva Pharmaceutical Industries Ltd. launched an authorized generic of Flector Patch (diclofenac patch) in U.S. The product launched by the company is an effective NSAID applied topically in order to treat acute pain due to minor contusions, sprain and strain.

This myofascial pain syndrome (MPS) treatment market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Myofascial Pain Syndrome (MPS) Treatment Market Scope and Market Size

Myofascial pain syndrome (MPS) treatment market is segmented on the basis of treatment, route of administration, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of treatment, the myofascial pain syndrome (MPS) treatment market is segmented into pharmacologic treatment and non- pharmacologic treatment.
• On the basis of route of administration, the myofascial pain syndrome (MPS) treatment market is segmented into oral, parenteral, topical and others.
• On the basis of end-users, the myofascial pain syndrome (MPS) treatment market is segmented into clinics, hospitals, homecare and others.
• On the basis of distribution channel, the myofascial pain syndrome (MPS) treatment market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy and others. 

Myofascial Pain Syndrome (MPS) Treatment Market Country Level Analysis

Myofascial pain syndrome (MPS) treatment market is analysed and market size information is provided by country, treatment, route of administration, end-users and distribution channel as referenced above.

The countries covered in the myofascial pain syndrome (MPS) treatment market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

On geographical estimation, North America accounts the largest market share due to the presence of huge number of chronic pain treatment clinics and high adoption of non-opiod pain management options. Moreover, rising governmental support and technological advancement is also boosting the growth of market.  Asia-Pacific is expected to account for the largest market share over coming years for the myofascial pain syndrome (MPS) treatment market due to the increasing geriatric population, increase in per capita income and improvement of healthcare infrastructure.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Myofascial pain syndrome (MPS) treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Myofascial pain syndrome (MPS) Treatment Market Share Analysis

Myofascial pain syndrome (MPS) treatment market competitive landscape provides details by competitor. details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to Myofascial pain syndrome (MPS) treatment market.

The major players covered in the Myofascial pain syndrome (MPS) treatment market report are Bliss GVS Pharma Limited, SAMYANG BIOPHARMACEUTICALS COPORATION, Jenburkt Pharmaceuticals Limited, Nemaura, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Acino International AG, Sun Pharmaceutical Industries Ltd., Avenue Therapeutics, Janssen Scientific Affairs, LLC, Dr. Reddy’s Laboratories Ltd., Teikoku Pharma USA, Inc., SCILEX Pharmaceuticals Inc., Amneal Pharmaceuticals LLC, Pfizer.Inc, Afton Pharma, Natco Pharma (Canada) Inc., Eli Lilly and Company, Aurobindo Pharma Limited, Cutting Edge Laser Technologies, Lightforce,  eToims, HOLLAR CHIROPRACTIC & RHAB among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

SKU-60894